Leerink Partners analyst Thomas Smith has reiterated their neutral stance on ALLK stock, giving a Hold rating on January 27.Invest with ...

In a report released yesterday, Sam Slutsky from LifeSci Capital maintained a Hold rating on Allakos (ALLK – Research Report), with a price ...

Kate Haviland, the Chief Executive Officer of Blueprint Medicines Corp (NASDAQ:BPMC), a biotechnology company with a market capitalization of $7.3 billion, has sold a portion of her holdings in the ...

Jeffrey W. Albers, a director at Blueprint Medicines Corp (NASDAQ:BPMC), recently executed significant stock transactions, ...

TL-895 is under development for the treatment of myelofibrosis, indolent systemic mastocytosis, chronic idiopathic myelofibrosis (primary myelofibrosis), post-polycythemia vera myelofibrosis (PPV-MF), ...

After being diagnosed with a rare disease—indolent systemic mastocytosis (ISM)—and starting on a treatment that has reduced her ISM symptoms, she continues to adapt and is inspired to help ...

Copyright: © 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

As his career progressed, the actor gained a deeper understanding of the lasting effects of slavery through the systemic racism he says he faced over his 30-year journey in the industry.

The most common subtype was mastocytosis in the skin (MIS) (48.9%), followed by indolent systemic mastocytosis (ISM) (30.6%), and SM with an associated hematologic neoplasm (SM-AHN) (11.0%). MIS is ...

BPMC stock rallies 18% on the company's optimistic 2025 outlook encompassing Ayvakit sales growth and pipeline progress.

Later, the drug’s label was expanded by respective regulatory authorities in both geographies to treat advanced and indolent systemic mastocytosis (SM). In the press release, BPMC has updated ...